HIOC is a selective tropomyosin-related kinase receptor B (TrkB) receptor agonist used in the treatment of early brain injury following subarachnoid hemorrhage (SAH). In addition it protects retinas from retinal degredation.
in vivo
HIOC (C57BL/6 mice, 50 mg/kg, IP, three times per week, for two weeks) increased survival of RGCs (retinal ganglion cells) after ONC (optic nerve crush)[3].
